{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2017-P-5787\" sorted by posted_date descending", "rows": [["FDA-2017-P-5787-0242", "FDA", "FDA-2017-P-5787", "Final Response Letter from FDA CDER to Post-Finasteride Syndrome Foundation", "Other", "Response(s)", "2022-06-09T04:00:00Z", 2022, 6, "2022-06-09T04:00:00Z", null, "2022-06-09T11:35:13Z", null, 0, 0, "090000648515084c"], ["FDA-2017-P-5787-0231", "FDA", "FDA-2017-P-5787", "Melcangi_Methylation of SRD5A2 in CSF of PFS Pts (Endocr Connect 2019)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T16:07:15Z", null, 0, 0, "0900006484984797"], ["FDA-2017-P-5787-0222", "FDA", "FDA-2017-P-5787", "CMDh Recommendation re Anxiety in Propecia SPC_EMA (Apr 2018)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T15:27:24Z", null, 0, 0, "0900006484984768"], ["FDA-2017-P-5787-0223", "FDA", "FDA-2017-P-5787", "Diviccaro_Finasteride, Hippocampal Neurogenesis and Neuroinflammation in Rats (Psychneuroendocrin 2019)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T15:28:17Z", null, 0, 0, "0900006484984769"], ["FDA-2017-P-5787-0230", "FDA", "FDA-2017-P-5787", "Levine_Court let Merck hide secrets (Reuters 9-11-19)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T16:06:26Z", null, 0, 0, "0900006484984796"], ["FDA-2017-P-5787-0232", "FDA", "FDA-2017-P-5787", "Nguyen and Trinh_Suicidality and Psychological AEs w Finasteride (JAMA Derm 2020)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T16:09:31Z", null, 0, 0, "0900006484984798"], ["FDA-2017-P-5787-0241", "FDA", "FDA-2017-P-5787", "Summary of Product Characteristics_ANSM_English (Dec 2019)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T16:34:25Z", null, 0, 0, "090000648498449a"], ["FDA-2017-P-5787-0224", "FDA", "FDA-2017-P-5787", "Gulbinovic_Final Assessment Report of PSUR (Sweden MPA 2007)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T15:29:58Z", null, 0, 0, "0900006484984791"], ["FDA-2017-P-5787-0235", "FDA", "FDA-2017-P-5787", "Petition Supplement 2 Post-Finasteride Syndrome Foundation", "Notice", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T17:17:17Z", null, 0, 0, "0900006484984494"], ["FDA-2017-P-5787-0226", "FDA", "FDA-2017-P-5787", "Kaufman_Finasteride Rx for AGA (J Am Acad Dermatol 1998)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T15:31:57Z", null, 0, 0, "0900006484984793"], ["FDA-2017-P-5787-0228", "FDA", "FDA-2017-P-5787", "Khera and Mirabel_Penile Vascular Abnormalities in PFS (Translat Androl Urol 2020)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T15:46:53Z", null, 0, 0, "0900006484984794"], ["FDA-2017-P-5787-0236", "FDA", "FDA-2017-P-5787", "Propecia Proposed Prescribing Info_Revision Marks (2002)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T16:27:53Z", null, 0, 0, "0900006484984495"], ["FDA-2017-P-5787-0238", "FDA", "FDA-2017-P-5787", "Propecia Summary of Product Characteristics_MHRA UK (Jun 2018)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T16:29:49Z", null, 0, 0, "0900006484984497"], ["FDA-2017-P-5787-0240", "FDA", "FDA-2017-P-5787", "Reminder of Risk of Psychiatric and Sexual Disorders_ANSM webpage (Feb 2019)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T16:33:26Z", null, 0, 0, "0900006484984499"], ["FDA-2017-P-5787-0237", "FDA", "FDA-2017-P-5787", "Propecia Summary of Product Characteristics_ANSM France (Dec 2019)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T16:28:52Z", null, 0, 0, "0900006484984496"], ["FDA-2017-P-5787-0225", "FDA", "FDA-2017-P-5787", "Irwig_Finasteride and Suicide Case Series (Dermatol 2020)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T15:30:45Z", null, 0, 0, "0900006484984792"], ["FDA-2017-P-5787-0229", "FDA", "FDA-2017-P-5787", "Letter to Health Professionals_Reminder of Risk of Psychiatric and Sexual Disorders_ANSM France (Feb 2019)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T15:52:35Z", null, 0, 0, "0900006484984795"], ["FDA-2017-P-5787-0227", "FDA", "FDA-2017-P-5787", "Godar and Bortolato_Finasteride Reduces Response to Stressful and Rewarding Stimuli (Biomolec 2019)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T15:41:44Z", null, 0, 0, "0900006484984790"], ["FDA-2017-P-5787-0233", "FDA", "FDA-2017-P-5787", "Periodic Safety Update Report _19_Merck (Nov 2006)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T16:24:23Z", null, 0, 0, "0900006484984799"], ["FDA-2017-P-5787-0234", "FDA", "FDA-2017-P-5787", "Petition Supplement 1 Post-Finasteride Syndrome Foundation", "Notice", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T17:16:41Z", null, 0, 0, "0900006484984493"], ["FDA-2017-P-5787-0239", "FDA", "FDA-2017-P-5787", "Red Hand Letter re Finasteride_BfArM Germany (Jul 2018)", "Supporting & Related Material", "Background Material", "2020-12-03T05:00:00Z", 2020, 12, null, null, "2020-12-03T16:30:50Z", null, 0, 0, "0900006484984498"], ["FDA-2017-P-5787-0221", "FDA", "FDA-2017-P-5787", "Interim Response from FDA to Post-Finasteride Syndrome Foundation", "Other", "Response(s)", "2018-03-16T04:00:00Z", 2018, 3, "2018-03-16T04:00:00Z", null, "2018-03-16T12:56:22Z", null, 0, 0, "090000648301baba"], ["FDA-2017-P-5787-0205", "FDA", "FDA-2017-P-5787", "Table of Contents re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "List", "2017-09-28T04:00:00Z", 2017, 9, null, null, "2017-09-29T12:56:49Z", null, 0, 0, "0900006482b732fe"], ["FDA-2017-P-5787-0065", "FDA", "FDA-2017-P-5787", "Reference 63 Hamilton_Male Hormone Stimulation and Baldness (Amer J Anat 1942) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:52:33Z", null, 0, 0, "0900006482b65d56"], ["FDA-2017-P-5787-0117", "FDA", "FDA-2017-P-5787", "Reference 115 MedWatch FDA Form 3500_PFSS#7 continued (30-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:56:06Z", null, 0, 0, "0900006482b65dbe"], ["FDA-2017-P-5787-0119", "FDA", "FDA-2017-P-5787", "Reference 117 MedWatch FDA Form 3500_PFSS#8 continued (28-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:56:12Z", null, 0, 0, "0900006482b65dc0"], ["FDA-2017-P-5787-0007", "FDA", "FDA-2017-P-5787", "Reference 5 Andersson_Cloned human and rat steroid 5\u03b1-reductases (PNAS 1990) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:44:54Z", null, 0, 0, "0900006482b650a9"], ["FDA-2017-P-5787-0011", "FDA", "FDA-2017-P-5787", "Reference 9 Antiandrogen Drugs Definition (Free Online Medical Dictionary, Thesaurus and Encyclopedia 2013) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:45:18Z", null, 0, 0, "0900006482b658b5"], ["FDA-2017-P-5787-0030", "FDA", "FDA-2017-P-5787", "Reference 28 Castro-Magana_Finasteride and Human Testicular Steroidogenesis (J Androl 1996) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:50:07Z", null, 0, 0, "0900006482b658d9"], ["FDA-2017-P-5787-0165", "FDA", "FDA-2017-P-5787", "Reference 163 Schultheiss_AR and ER in Human Corpus Cavernosum (World J Urol 2003) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:59:15Z", null, 0, 0, "0900006482b65e86"], ["FDA-2017-P-5787-0191", "FDA", "FDA-2017-P-5787", "Reference 189 Trybek_AR in the Epididymis of Rats with DHT Deficiency (Reprod Biol 2005) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:01:01Z", null, 0, 0, "0900006482b65ebe"], ["FDA-2017-P-5787-0021", "FDA", "FDA-2017-P-5787", "Reference 19 Bruchovsky_Intranuclear Binding of T in Rat Prostate (J Biol Chem 1968) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:49:28Z", null, 0, 0, "0900006482b65920"], ["FDA-2017-P-5787-0023", "FDA", "FDA-2017-P-5787", "Reference 21 Bull_Mechanism-Based Inhibition of Human 5AR (J Am Chem Soc 1996) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:49:37Z", null, 0, 0, "0900006482b65922"], ["FDA-2017-P-5787-0106", "FDA", "FDA-2017-P-5787", "Reference 104 MedWatch FDA Form 3500_PFSS#2 3500 (24-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:55:19Z", null, 0, 0, "0900006482b65ab0"], ["FDA-2017-P-5787-0115", "FDA", "FDA-2017-P-5787", "Reference 113 MedWatch FDA Form 3500_PFSS#6 continued (29-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:55:59Z", null, 0, 0, "0900006482b65acd"], ["FDA-2017-P-5787-0116", "FDA", "FDA-2017-P-5787", "Reference 114 MedWatch FDA Form 3500_PFSS#7 (30-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:56:03Z", null, 0, 0, "0900006482b65ace"], ["FDA-2017-P-5787-0129", "FDA", "FDA-2017-P-5787", "Reference 127 Nonomura_Androgen Binding in Mammalian Penis (J Urol 1990) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:56:47Z", null, 0, 0, "0900006482b65afe"], ["FDA-2017-P-5787-0184", "FDA", "FDA-2017-P-5787", "Reference 182 Tindall_5ARIs in PC (J Urol 2008) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:00:26Z", null, 0, 0, "0900006482b65b79"], ["FDA-2017-P-5787-0029", "FDA", "FDA-2017-P-5787", "Reference 27 Castelli_Regional Distribution of 5AR2 in Rat Brain_Table 1 (Psychoneuroendocrin 2013) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:50:02Z", null, 0, 0, "0900006482b658d8"], ["FDA-2017-P-5787-0157", "FDA", "FDA-2017-P-5787", "Reference 155 Roberts_Clinical Dose Ranging Studies w Finasteride for  MPHL (J Am Acad Dermatol 1999) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:58:46Z", null, 0, 0, "0900006482b65e58"], ["FDA-2017-P-5787-0075", "FDA", "FDA-2017-P-5787", "Reference 73 Irwig_Finasteride and Persistent Sexual Side Effects (J Sex Med 2011) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:53:18Z", null, 0, 0, "0900006482b65a24"], ["FDA-2017-P-5787-0087", "FDA", "FDA-2017-P-5787", "Reference 85 Ko_CDER Medical Review_NDA 20-788_P3 (Dec-1997) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:54:02Z", null, 0, 0, "0900006482b65a87"], ["FDA-2017-P-5787-0198", "FDA", "FDA-2017-P-5787", "Reference 196 Wessells_PLESS_Sexual AEs in BPH (Urology 2003) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:01:25Z", null, 0, 0, "0900006482b65ba8"], ["FDA-2017-P-5787-0201", "FDA", "FDA-2017-P-5787", "Reference 199 Wu_Reproductive AEs w Alopecia Drugs (Oncotarget 2016) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:01:35Z", null, 0, 0, "0900006482b65bab"], ["FDA-2017-P-5787-0141", "FDA", "FDA-2017-P-5787", "Reference 139 Presti_Finasteride for Stage D PC (J Urol 1992) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:57:35Z", null, 0, 0, "0900006482b65e1e"], ["FDA-2017-P-5787-0101", "FDA", "FDA-2017-P-5787", "Reference 99 Mantzoros_DHT and Male Sexual Behavior (BMJ 1995) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:55:02Z", null, 0, 0, "0900006482b65aab"], ["FDA-2017-P-5787-0134", "FDA", "FDA-2017-P-5787", "Reference 132 Park_Androgens and NOS mRNA in Rat Corpus Cavernosum (BJU Int 1999) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:57:07Z", null, 0, 0, "0900006482b65b03"], ["FDA-2017-P-5787-0145", "FDA", "FDA-2017-P-5787", "Reference 143 Propecia Full Prescribing Info (31-Jan-2014) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:57:51Z", null, 0, 0, "0900006482b65b27"], ["FDA-2017-P-5787-0178", "FDA", "FDA-2017-P-5787", "Reference 176 Suzuki_PK and Binding of Finasteride to 5AR1 and 5AR2 (Drug Metab Pharmacokin 2010)", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:00:04Z", null, 0, 0, "0900006482b65b73"], ["FDA-2017-P-5787-0179", "FDA", "FDA-2017-P-5787", "Reference 177 Tay_Finasteride in Adenoca of Prostate (Ann Onc 2004) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:00:08Z", null, 0, 0, "0900006482b65b74"], ["FDA-2017-P-5787-0139", "FDA", "FDA-2017-P-5787", "Reference 137 Poletti_Androgen Activating Enzymes in CNS (J Steroid Biochem Mol Biol 1999) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:57:28Z", null, 0, 0, "0900006482b65e1c"], ["FDA-2017-P-5787-0143", "FDA", "FDA-2017-P-5787", "Reference 141 Propecia Full Prescribing Info (8-Dec-2001) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:57:43Z", null, 0, 0, "0900006482b65e20"], ["FDA-2017-P-5787-0071", "FDA", "FDA-2017-P-5787", "Reference 69 Imperato-McGinley_C19 and C21 Metabolites w Finasteride and 5AR2 Deficiency (JCEM 1990) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:53:04Z", null, 0, 0, "0900006482b65a20"], ["FDA-2017-P-5787-0057", "FDA", "FDA-2017-P-5787", "Reference 55 Glina_Finasteride and Infertility (Rev Hosp Clin 2004) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:52:04Z", null, 0, 0, "0900006482b65d4e"], ["FDA-2017-P-5787-0060", "FDA", "FDA-2017-P-5787", "Reference 58 Gormley_Treating AGA with 5-Alpha Reductase Inhibitors_U.S. Patent # 5,547,957 (20-Aug-1996) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:52:15Z", null, 0, 0, "0900006482b65d51"], ["FDA-2017-P-5787-0012", "FDA", "FDA-2017-P-5787", "Reference 10 Aumuller_Localization of 5AR Isoenzymes in Human Tissue (Acta Anat 1996) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:45:22Z", null, 0, 0, "0900006482b658b6"], ["FDA-2017-P-5787-0028", "FDA", "FDA-2017-P-5787", "Reference 26 Castelli_Regional Distribution of 5AR2 in Rat Brain (Psychoneuroendocrin 2013) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:49:59Z", null, 0, 0, "0900006482b658d7"], ["FDA-2017-P-5787-0054", "FDA", "FDA-2017-P-5787", "Reference 52 Geller_Castration-Like Effects of Finasteride on Prostate (J Cell Biochem 1992) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:51:52Z", null, 0, 0, "0900006482b659f2"], ["FDA-2017-P-5787-0069", "FDA", "FDA-2017-P-5787", "Reference 67 Imperato-McGinley_5AR Deficiency and Pseudohermaphrotism (Science 1974) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:52:57Z", null, 0, 0, "0900006482b65a1e"], ["FDA-2017-P-5787-0093", "FDA", "FDA-2017-P-5787", "Reference 91 Labrie_Serum Steroid Precursors and Androgen Metabolites (J Clin Endocrinol Metab 1997) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:54:33Z", null, 0, 0, "0900006482b65a8d"], ["FDA-2017-P-5787-0199", "FDA", "FDA-2017-P-5787", "Reference 197 Whiting_Finasteride 1 mg in MPHL age 41-60 (Eur J Dermotol 2003) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:01:28Z", null, 0, 0, "0900006482b65ba9"], ["FDA-2017-P-5787-0202", "FDA", "FDA-2017-P-5787", "Reference 200 Yamana_Type 3 5AR inhibition by finasteride and dutasteride (Horm Mol Clin Invest 2010) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:01:38Z", null, 0, 0, "0900006482b65bac"], ["FDA-2017-P-5787-0098", "FDA", "FDA-2017-P-5787", "Reference 96 Lugg_DHT and NO Penile Erection in the the Rat (Endocrin 1995) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:54:50Z", null, 0, 0, "0900006482b65aa8"], ["FDA-2017-P-5787-0111", "FDA", "FDA-2017-P-5787", "Reference 109 MedWatch FDA Form 3500_PFSS#4 continued (26-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:55:46Z", null, 0, 0, "0900006482b65ac9"], ["FDA-2017-P-5787-0127", "FDA", "FDA-2017-P-5787", "Reference 125 Moore_Finasteride and Uncertainty in Establishing Harm (JAMA Derm 2015) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:56:39Z", null, 0, 0, "0900006482b65afa"], ["FDA-2017-P-5787-0131", "FDA", "FDA-2017-P-5787", "Reference 129 O'Donnell_T-Dependent Spermatogenesis in Rats and 5ARI (J Androl 1999) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:56:56Z", null, 0, 0, "0900006482b65b00"], ["FDA-2017-P-5787-0152", "FDA", "FDA-2017-P-5787", "Reference 150 Rittmaster_Adiol-G in Liver, Skin and Prostate (JCEM 1993) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:58:25Z", null, 0, 0, "0900006482b65b2e"], ["FDA-2017-P-5787-0180", "FDA", "FDA-2017-P-5787", "Reference 178 The Pharma Letter_FDA C'tee Raises Concerns Over Merck's Propecia (11-19-97) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:00:11Z", null, 0, 0, "0900006482b65b75"], ["FDA-2017-P-5787-0181", "FDA", "FDA-2017-P-5787", "Reference 179 The Pharma Letter_Propecia Approved in US for MPB (1-12-98) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:00:15Z", null, 0, 0, "0900006482b65b76"], ["FDA-2017-P-5787-0086", "FDA", "FDA-2017-P-5787", "Reference 84 Ko_CDER Medical Review_NDA 20-788_P2 (Dec-1997) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:54:00Z", null, 0, 0, "0900006482b65d81"], ["FDA-2017-P-5787-0121", "FDA", "FDA-2017-P-5787", "Reference 119 Melcangi_CSF Neurosteroid Levels in PFS (JSM 2013) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:56:19Z", null, 0, 0, "0900006482b65dc2"], ["FDA-2017-P-5787-0128", "FDA", "FDA-2017-P-5787", "Reference 126 Nickel_PROSPECT Study in BPH (Can Med Assoc J 1996)_ re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:56:43Z", null, 0, 0, "0900006482b65afd"], ["FDA-2017-P-5787-0146", "FDA", "FDA-2017-P-5787", "Reference 144 Propecia Selected Safety Information - Not an Antiandrogen (Propecia Website 10-5-08) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:57:55Z", null, 0, 0, "0900006482b65b28"], ["FDA-2017-P-5787-0003", "FDA", "FDA-2017-P-5787", "Reference 1 Ali_Pharmacovigil of Persistent SD and Suicidal Ideation w Finasteride (Pharmacother 2015) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:44:39Z", null, 0, 0, "0900006482b650a5"], ["FDA-2017-P-5787-0015", "FDA", "FDA-2017-P-5787", "Reference 13 Basaria_Characteristics of Men w Persistent SD after Finasteride for AGA_supplementary appendix (JCEM 2016) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:45:33Z", null, 0, 0, "0900006482b658b9"], ["FDA-2017-P-5787-0017", "FDA", "FDA-2017-P-5787", "Reference 15 Belelli_Neurosteroids and the GABA-A Receptor (Nat Rev Neurosci 2005) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:45:39Z", null, 0, 0, "0900006482b658bb"], ["FDA-2017-P-5787-0032", "FDA", "FDA-2017-P-5787", "Reference 30 Celotti_Steroid Metabolism in the Mammalian Brain (Brain Res Bull 1997) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:50:21Z", null, 0, 0, "0900006482b658db"], ["FDA-2017-P-5787-0034", "FDA", "FDA-2017-P-5787", "Reference 32 Charmandari_DHT Administration in Children (Horm Res 2001) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:50:28Z", null, 0, 0, "0900006482b658dd"], ["FDA-2017-P-5787-0162", "FDA", "FDA-2017-P-5787", "Reference 160 Sawaya_Novel Agents for the Treatment of Alopecia (Semin Cut Med Surg 1998) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:59:04Z", null, 0, 0, "0900006482b65e5d"], ["FDA-2017-P-5787-0169", "FDA", "FDA-2017-P-5787", "Reference 167 Shukla_Finasteride Analysis of Comparative of Pharmacodynamic effects of 1 mg and 5 mg  Finasteride Dose_ ID 3046462 (1-Jun-2011) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:59:29Z", null, 0, 0, "0900006482b65e8a"], ["FDA-2017-P-5787-0053", "FDA", "FDA-2017-P-5787", "Reference 51 Gao_Chemistry and Structural Biology of AR (Chem Rev 2005) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:51:49Z", null, 0, 0, "0900006482b659f1"], ["FDA-2017-P-5787-0055", "FDA", "FDA-2017-P-5787", "Reference 53 Giatti_Effects of Subchronic Finasteride Rx and Withdrawal in Male Rat Brain (Neuroendocrin 2015) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:51:56Z", null, 0, 0, "0900006482b659f3"], ["FDA-2017-P-5787-0072", "FDA", "FDA-2017-P-5787", "Reference 70 Ioannidis_Safety Reporting in RCTs (JAMA 2001) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:53:08Z", null, 0, 0, "0900006482b65a21"], ["FDA-2017-P-5787-0074", "FDA", "FDA-2017-P-5787", "Reference 72 Irwig_Depressive and Suicidal Sx in PFS (J Clin Psych 2012) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:53:15Z", null, 0, 0, "0900006482b65a23"], ["FDA-2017-P-5787-0096", "FDA", "FDA-2017-P-5787", "Reference 94 Lewis_Effect of Androgen on Penile Tissue (Endocrine 2004) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:54:43Z", null, 0, 0, "0900006482b65a90"], ["FDA-2017-P-5787-0204", "FDA", "FDA-2017-P-5787", "Reference 202 Zhang_Finasteride and ED in Rat Model (J Sex Med 2012) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:01:45Z", null, 0, 0, "0900006482b65bae"], ["FDA-2017-P-5787-0140", "FDA", "FDA-2017-P-5787", "Reference 138 Prescriber Update_Post Finasteride Syndrome (New Zealand 29-Apr-2016) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:57:32Z", null, 0, 0, "0900006482b65e1d"], ["FDA-2017-P-5787-0158", "FDA", "FDA-2017-P-5787", "Reference 156 Romer_Finasteride Inhibits Hippocampal Neurogenesis in Mice (Pharmacopsych 2010) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:58:49Z", null, 0, 0, "0900006482b65e59"], ["FDA-2017-P-5787-0159", "FDA", "FDA-2017-P-5787", "Reference 157 Ruizeveld de Winter_AR Expression in Human Tissues (J Histochem Cytochem 1991) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:58:53Z", null, 0, 0, "0900006482b65e5a"], ["FDA-2017-P-5787-0190", "FDA", "FDA-2017-P-5787", "Reference 188 Traish_Glucose, Lipids and SD w Dutasteride for BPH (Horm Mol Biol Clin Invest 2017) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T21:00:50Z", null, 0, 0, "0900006482b65ebd"], ["FDA-2017-P-5787-0059", "FDA", "FDA-2017-P-5787", "Reference 57 Gormley_MK-906 and Circulating Androgens (J Clin Endocr Metab 1990) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:52:11Z", null, 0, 0, "0900006482b65d50"], ["FDA-2017-P-5787-0118", "FDA", "FDA-2017-P-5787", "Reference 116 MedWatch FDA Form 3500_PFSS#8 (28-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:56:09Z", null, 0, 0, "0900006482b65dbf"], ["FDA-2017-P-5787-0105", "FDA", "FDA-2017-P-5787", "Reference 103 MedWatch FDA Form 3500_PFSS#1 continued (24-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:55:16Z", null, 0, 0, "0900006482b65aaf"], ["FDA-2017-P-5787-0132", "FDA", "FDA-2017-P-5787", "Reference 130 Overstreet_Finasteride, Spermatogenesis and Semen Production (J Urol 1999) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:57:00Z", null, 0, 0, "0900006482b65b01"], ["FDA-2017-P-5787-0151", "FDA", "FDA-2017-P-5787", "Reference 149 Rasmusson_Treating AGA with Finasteride _U.S. Patent # 5,571,817 (5-Nov-1996) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:58:22Z", null, 0, 0, "0900006482b65b2d"], ["FDA-2017-P-5787-0153", "FDA", "FDA-2017-P-5787", "Reference 151 Rittmaster_Apoptosis of Prostate in Men given Finasteride (JCEM 1996) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:58:29Z", null, 0, 0, "0900006482b65b2f"], ["FDA-2017-P-5787-0061", "FDA", "FDA-2017-P-5787", "Reference 59 Grino_Phase III Studies of Finasteride for BPH (Eur Urol 1994) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:52:18Z", null, 0, 0, "0900006482b65d52"], ["FDA-2017-P-5787-0085", "FDA", "FDA-2017-P-5787", "Reference 83 Ko_CDER Medical Review_NDA 20-788_P1 (Dec-1997) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:53:56Z", null, 0, 0, "0900006482b65d80"], ["FDA-2017-P-5787-0125", "FDA", "FDA-2017-P-5787", "Reference 123 MK-906 Protocol_PLESS Trial (20-Nov-1991) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:56:33Z", null, 0, 0, "0900006482b65dc6"], ["FDA-2017-P-5787-0005", "FDA", "FDA-2017-P-5787", "Reference 3 Amendments to Propecia Mktg Authorisation (CMDh Apr-2017) re Citizen Petition Post- Finasteride Syndrome Foundation", "Supporting & Related Material", "Background Material", "2017-09-21T04:00:00Z", 2017, 9, null, null, "2017-09-21T20:44:47Z", null, 0, 0, "0900006482b650a7"]], "truncated": false, "filtered_table_rows_count": 227, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 order by posted_date desc limit 101", "params": {"p0": "FDA-2017-P-5787"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2017-P-5787", "results": [{"value": "FDA", "label": "FDA", "count": 227, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2017-P-5787", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 221, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Other", "label": "Other", "count": 4, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&document_type=Other", "selected": false}, {"value": "Notice", "label": "Notice", "count": 2, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&document_type=Notice", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2017-P-5787", "results": [{"value": 2017, "label": 2017, "count": 205, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&posted_year=2017", "selected": false}, {"value": 2020, "label": 2020, "count": 20, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&posted_year=2020", "selected": false}, {"value": 2018, "label": 2018, "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&posted_year=2018", "selected": false}, {"value": 2022, "label": 2022, "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&posted_year=2022", "selected": false}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&_facet=comment_start_date"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&_facet_date=last_modified"}], "next": "2017-09-21T04~3A00~3A00Z,FDA-2017-P-5787-0005", "next_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2017-P-5787&_next=2017-09-21T04~3A00~3A00Z%2CFDA-2017-P-5787-0005&_sort_desc=posted_date", "private": false, "allow_execute_sql": true, "query_ms": 9.87128703854978, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}